TBPH Quote, Financials, Valuation and Earnings

Ironwood Pharmaceuticals has a net margin of -88.24% compared to Theravance Biopharma's net margin of -90.87%. Theravance Biopharma's return on equity of -31.51% beat Ironwood Pharmaceuticals's return on equity of --.

Theravance Biopharma has a consensus price target of $17.20, signalling upside risk potential of 47.64%. On the other hand Ironwood Pharmaceuticals has an analysts' consensus of $0.95 which suggests that it could grow by 20.13%. Given that Theravance Biopharma has higher upside potential than Ironwood Pharmaceuticals, analysts believe Theravance Biopharma is more attractive than Ironwood Pharmaceuticals.

Theravance Biopharma has a beta of -0.018, which suggesting that the stock is 101.836% less volatile than S&P 500. In comparison Ironwood Pharmaceuticals has a beta of 0.297, suggesting its less volatile than the S&P 500 by 70.313%.

Theravance Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ironwood Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theravance Biopharma pays -- of its earnings as a dividend. Ironwood Pharmaceuticals pays out -- of its earnings as a dividend.

Theravance Biopharma quarterly revenues are $15.4M, which are smaller than Ironwood Pharmaceuticals quarterly revenues of $41.1M. Theravance Biopharma's net income of -$13.6M is higher than Ironwood Pharmaceuticals's net income of -$37.4M. Notably, Theravance Biopharma's price-to-earnings ratio is -- while Ironwood Pharmaceuticals's PE ratio is 126.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theravance Biopharma is 8.78x versus 0.40x for Ironwood Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -88.24% compared to Theravance Biopharma's net margin of 23.32%. Theravance Biopharma's return on equity of -31.51% beat Johnson & Johnson's return on equity of 30.18%.

Theravance Biopharma has a consensus price target of $17.20, signalling upside risk potential of 47.64%. On the other hand Johnson & Johnson has an analysts' consensus of $173.66 which suggests that it could grow by 6.55%. Given that Theravance Biopharma has higher upside potential than Johnson & Johnson, analysts believe Theravance Biopharma is more attractive than Johnson & Johnson.

Theravance Biopharma has a beta of -0.018, which suggesting that the stock is 101.836% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.579%.

Theravance Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.08% to investors and pays a quarterly dividend of $1.30 per share. Theravance Biopharma pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Theravance Biopharma quarterly revenues are $15.4M, which are smaller than Johnson & Johnson quarterly revenues of $23.7B. Theravance Biopharma's net income of -$13.6M is lower than Johnson & Johnson's net income of $5.5B. Notably, Theravance Biopharma's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 17.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theravance Biopharma is 8.78x versus 4.36x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -88.24% compared to Theravance Biopharma's net margin of 21.68%. Theravance Biopharma's return on equity of -31.51% beat Eli Lilly and's return on equity of 78.25%.

Theravance Biopharma has a consensus price target of $17.20, signalling upside risk potential of 47.64%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 25.05%. Given that Theravance Biopharma has higher upside potential than Eli Lilly and, analysts believe Theravance Biopharma is more attractive than Eli Lilly and.

Theravance Biopharma has a beta of -0.018, which suggesting that the stock is 101.836% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Theravance Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Theravance Biopharma pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Theravance Biopharma quarterly revenues are $15.4M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Theravance Biopharma's net income of -$13.6M is lower than Eli Lilly and's net income of $2.8B. Notably, Theravance Biopharma's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 61.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theravance Biopharma is 8.78x versus 14.04x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Viatris has a net margin of -88.24% compared to Theravance Biopharma's net margin of -93.48%. Theravance Biopharma's return on equity of -31.51% beat Viatris's return on equity of -20.24%.

Theravance Biopharma has a consensus price target of $17.20, signalling upside risk potential of 47.64%. On the other hand Viatris has an analysts' consensus of $11.3875 which suggests that it could grow by 25.41%. Given that Theravance Biopharma has higher upside potential than Viatris, analysts believe Theravance Biopharma is more attractive than Viatris.

Theravance Biopharma has a beta of -0.018, which suggesting that the stock is 101.836% less volatile than S&P 500. In comparison Viatris has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.435%.

Theravance Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris offers a yield of 5.29% to investors and pays a quarterly dividend of $0.12 per share. Theravance Biopharma pays -- of its earnings as a dividend. Viatris pays out -90.63% of its earnings as a dividend.

Theravance Biopharma quarterly revenues are $15.4M, which are smaller than Viatris quarterly revenues of $3.3B. Theravance Biopharma's net income of -$13.6M is higher than Viatris's net income of -$3B. Notably, Theravance Biopharma's price-to-earnings ratio is -- while Viatris's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theravance Biopharma is 8.78x versus 0.76x for Viatris. Usually stocks with elevated PS ratios are considered overvalued.